Good many DNDN shareholders are not investors at all.
Let us see what is going on: 1. The good news - Provenge is potentially a revolutionary and survival extension drug with few sideeffects - Provenge is an immune boosting medication
2. The bad news - DNDN management is a total POS, i.e., it is totally incompetent and overwhelmingly greedy - There are almost no clinical trial to support future Provenge use and marketing - Provenge supply is very limited now and for the next 12 months - DNDN has no marketing and/or promotion expertise and real sale capabilities
3. The very bad news -- J&J Zytiga just got approved. - It is an immunosuppressant medication. It cannot be used with Provenge at the same time. - It is a pill and its supply is plentiful. Therefore, cancer patients will not wait for the Provenge availability and will start using Zytiga. These patients are lost for future Provenge use. - Zytiga are much cheaper with no need for insurers to pay additional doctors' administration fees. Consequently, insurers will strongly promoting Zytiga off-label use instead of using Provenge. - As for the ROW, J&J already has filled its marketing applications in Europe. As for DNDN, nobody sure when Provenge applications will be filled in Europe. J&J has all marketing, sale , and manufacturing force already in place in ROW but DNDN has nothing
The bottom Line I am planning to short DNDN in the next few days.
You missed one little detail; that is, Abiraterone's label is post-chemo whereas Provenge label is first line mestastic pre-chemo. In other words, for the current labels, Abiraterone and Provenge are not competitors.
Just goes to show--long winded posts like yours are usually BS.